We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
TMO Q3 Earnings & Revenues Beat Estimates, Stock Down in Pre-Market
Read MoreHide Full Article
Key Takeaways
TMO's Q3 earnings rose 15% to $6.68 per share as revenues grew 9% to $12.14 billion, beating estimates.
TMO's adjusted operating margin widened 120 bps to 24.5%, with profitability improving across all segments.
Thermo Fisher's biopharma services business grew 15%, while Specialty Diagnostics revenues declined 6.5%.
Thermo Fisher Scientific Inc. (TMO - Free Report) delivered third-quarter 2026 adjusted earnings of $6.68 per share, up 15% year over year. The figure beat the Zacks Consensus Estimate by 4.4%.
Revenues rose 9% to $12.14 billion and surpassed the consensus mark of $11.92 billion by 1.8%. Results were supported by 6% organic revenue growth and improved operating profitability, reflecting the strength of the company's growth strategy and PPI Business System.
Following the earnings announcement, TMO stock fell 4.1% in pre-market trading today.
TMO's Q3 Segmental Performance Shows Mixed Trends
Life Sciences Solutions revenues increased 5.1% year over year to $2.72 billion. Segment income rose to $1.02 billion from $968 million, while the segment income margin expanded 20 basis points (bps) to 37.6%.
Laboratory Products and Biopharma Services remained the largest business, with revenues climbing 15% to $6.86 billion. Segment income increased to $1.07 billion from $868 million, while margin improved to 15.5% from 14.5%. The segment accounted for 56.5% of consolidated revenues before eliminations.
Analytical Instruments revenues advanced 5.8% year over year to $2 billion. Segment income jumped to $538 million from $429 million, driving margin expansion to 26.9% from 22.6%. The 430-bps improvement was the largest among the company's four segments.
Specialty Diagnostics revenues declined 6.5% to $1.1 billion. However, segment income increased to $341 million from $321 million, while margin expanded to 31% from 27.4%. The improvement in profitability despite lower revenues highlights the segment's stronger operating efficiency.
TMO Expands Operating Profitability
Adjusted operating income increased 15% year over year to $2.97 billion. The adjusted operating margin widened 120 bps to 24.5%, reflecting profitability improvements across all four business segments.
On a GAAP basis, operating income rose 17% to $2.26 billion, while the operating margin improved to 18.6% from 17.4%. The cost of revenues totaled $6.95 billion, selling, general and administrative expenses were $1.86 billion, and research and development spending amounted to $348 million. GAAP earnings per share increased 9% to $4.64.
Thermo Fisher ended the third quarter with cash and cash equivalents of $5.46 billion compared with $9.85 billion at the end of 2025. Total assets stood at $114.23 billion, while long-term obligations amounted to $39.11 billion.
For the first nine months of 2026, net cash provided by operating activities increased to $5.87 billion from $4.36 billion a year earlier. Free cash flow rose to $4.62 billion from $3.32 billion. During this period, acquisitions net of cash acquired totaled $8.88 billion, share repurchases reached $4 billion, and dividends paid amounted to $511 million.
Thermo Fisher Deepens Partnerships and Capabilities
Thermo Fisher partnered with Mayo Clinic to launch Precure, an initiative combining data from more than one million patient samples with its proteomics technologies. The collaboration aims to advance disease research, earlier detection and precision medicine.
The company also opened its first AI-Automation Innovation Center in South Korea to help customers accelerate innovation and research productivity. Additionally, a highly automated distribution center in Kentucky expanded its North American supply capabilities. Thermo Fisher completed the previously announced divestiture of its microbiology business during the quarter.
Management highlighted the effectiveness of its growth strategy and operational execution. Chairman and CEO Marc N. Casper expressed confidence in delivering strong results for 2026 and creating long-term stakeholder value. The company is scheduled to provide updated full-year financial guidance during its Oct. 21 earnings conference call.
Thermo Fisher Scientific Inc. Price, Consensus and EPS Surprise
Thermo Fisher ended the third quarter with both earnings and revenues beating respective estimates. Performance reflected the strength of the company’s proven growth strategy, strong execution and the power of the PPI Business System. Expansion of the adjusted operating margin in the quarter is also very promising.
During the quarter, Thermo Fisher launched the Orbitrap Isora mass spectrometer — its first Orbitrap system designed for isotope ratio analysis — enabling faster workflows and deeper insights into sample composition. Other launches included the EMPAD G2 electron detector for advanced materials characterization and the FDA-cleared EliA CTD 13 Screen for systemic connective tissue diseases. The company also introduced the Ion 560 Chip, offering nearly twice the sequencing capacity of its predecessor to support growing genomic profiling requirements.
TMO’s Zacks Rank & Key Picks
Thermo Fisher currently carries a Zacks Rank #3 (Hold).
Some top-ranked stocks from the broader Computer and Technology sector are Micron Technology (MU - Free Report) , Richardson Electronics, Ltd. (RELL - Free Report) and Ciena (CIEN - Free Report) .
Micron Technology, sporting a Zacks Rank #1 (Strong Buy) at present, reported a fourth-quarter fiscal 2026 EPS of $33.42, which beat the Zacks Consensus Estimate by 5.73%. Revenues of $54.23 billion surpassed the Zacks Consensus Estimate by 6.33%. You can see the complete list of today’s Zacks #1 Rank stocks here.
MU has an earnings yield of 18.7% compared with the industry’s 4.5% yield. The company surpassed earnings estimates in each of the trailing four quarters, the average surprise being 21%.
Richardson Electronics, currently sporting a Zacks Rank #1, posted a first-quarter fiscal 2027 EPS of 27 cents, topping the Zacks Consensus Estimate by 200%. Revenues of $64.92 million beat the Zacks Consensus Estimate by 10.07%.
RELL has an estimated fiscal 2027 earnings growth rate of 62.5% compared with the industry’s 46.2% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 110%.
Ciena, sporting a Zacks Rank #1 at present, reported third-quarter fiscal 2026 EPS of $2.11, which topped the Zacks Consensus Estimate by 21.26%. Revenues of $1.67 billion surpassed the consensus mark by 1.44%.
CIEN has an estimated fiscal 2026 earnings growth rate of 171.2% compared with the industry’s 35.3% growth. The company’s earnings beat estimates in each of the trailing four quarters and matched on one occasion, the average surprise being 17.55%.
View the Zacks #1 Rank List
Image: Bigstock
TMO Q3 Earnings & Revenues Beat Estimates, Stock Down in Pre-Market
Key Takeaways
Thermo Fisher Scientific Inc. (TMO - Free Report) delivered third-quarter 2026 adjusted earnings of $6.68 per share, up 15% year over year. The figure beat the Zacks Consensus Estimate by 4.4%.
Revenues rose 9% to $12.14 billion and surpassed the consensus mark of $11.92 billion by 1.8%. Results were supported by 6% organic revenue growth and improved operating profitability, reflecting the strength of the company's growth strategy and PPI Business System.
Following the earnings announcement, TMO stock fell 4.1% in pre-market trading today.
TMO's Q3 Segmental Performance Shows Mixed Trends
Life Sciences Solutions revenues increased 5.1% year over year to $2.72 billion. Segment income rose to $1.02 billion from $968 million, while the segment income margin expanded 20 basis points (bps) to 37.6%.
Laboratory Products and Biopharma Services remained the largest business, with revenues climbing 15% to $6.86 billion. Segment income increased to $1.07 billion from $868 million, while margin improved to 15.5% from 14.5%. The segment accounted for 56.5% of consolidated revenues before eliminations.
Thermo Fisher's Analytical Instruments Margin Widens
Analytical Instruments revenues advanced 5.8% year over year to $2 billion. Segment income jumped to $538 million from $429 million, driving margin expansion to 26.9% from 22.6%. The 430-bps improvement was the largest among the company's four segments.
Specialty Diagnostics revenues declined 6.5% to $1.1 billion. However, segment income increased to $341 million from $321 million, while margin expanded to 31% from 27.4%. The improvement in profitability despite lower revenues highlights the segment's stronger operating efficiency.
TMO Expands Operating Profitability
Adjusted operating income increased 15% year over year to $2.97 billion. The adjusted operating margin widened 120 bps to 24.5%, reflecting profitability improvements across all four business segments.
On a GAAP basis, operating income rose 17% to $2.26 billion, while the operating margin improved to 18.6% from 17.4%. The cost of revenues totaled $6.95 billion, selling, general and administrative expenses were $1.86 billion, and research and development spending amounted to $348 million. GAAP earnings per share increased 9% to $4.64.
Thermo Fisher's Q3 Cash Flow Supports Financial Strength
Thermo Fisher ended the third quarter with cash and cash equivalents of $5.46 billion compared with $9.85 billion at the end of 2025. Total assets stood at $114.23 billion, while long-term obligations amounted to $39.11 billion.
For the first nine months of 2026, net cash provided by operating activities increased to $5.87 billion from $4.36 billion a year earlier. Free cash flow rose to $4.62 billion from $3.32 billion. During this period, acquisitions net of cash acquired totaled $8.88 billion, share repurchases reached $4 billion, and dividends paid amounted to $511 million.
Thermo Fisher Deepens Partnerships and Capabilities
Thermo Fisher partnered with Mayo Clinic to launch Precure, an initiative combining data from more than one million patient samples with its proteomics technologies. The collaboration aims to advance disease research, earlier detection and precision medicine.
The company also opened its first AI-Automation Innovation Center in South Korea to help customers accelerate innovation and research productivity. Additionally, a highly automated distribution center in Kentucky expanded its North American supply capabilities. Thermo Fisher completed the previously announced divestiture of its microbiology business during the quarter.
Management highlighted the effectiveness of its growth strategy and operational execution. Chairman and CEO Marc N. Casper expressed confidence in delivering strong results for 2026 and creating long-term stakeholder value. The company is scheduled to provide updated full-year financial guidance during its Oct. 21 earnings conference call.
Thermo Fisher Scientific Inc. Price, Consensus and EPS Surprise
Thermo Fisher Scientific Inc. price-consensus-eps-surprise-chart | Thermo Fisher Scientific Inc. Quote
Our Take
Thermo Fisher ended the third quarter with both earnings and revenues beating respective estimates. Performance reflected the strength of the company’s proven growth strategy, strong execution and the power of the PPI Business System. Expansion of the adjusted operating margin in the quarter is also very promising.
During the quarter, Thermo Fisher launched the Orbitrap Isora mass spectrometer — its first Orbitrap system designed for isotope ratio analysis — enabling faster workflows and deeper insights into sample composition. Other launches included the EMPAD G2 electron detector for advanced materials characterization and the FDA-cleared EliA CTD 13 Screen for systemic connective tissue diseases. The company also introduced the Ion 560 Chip, offering nearly twice the sequencing capacity of its predecessor to support growing genomic profiling requirements.
TMO’s Zacks Rank & Key Picks
Thermo Fisher currently carries a Zacks Rank #3 (Hold).
Some top-ranked stocks from the broader Computer and Technology sector are Micron Technology (MU - Free Report) , Richardson Electronics, Ltd. (RELL - Free Report) and Ciena (CIEN - Free Report) .
Micron Technology, sporting a Zacks Rank #1 (Strong Buy) at present, reported a fourth-quarter fiscal 2026 EPS of $33.42, which beat the Zacks Consensus Estimate by 5.73%. Revenues of $54.23 billion surpassed the Zacks Consensus Estimate by 6.33%. You can see the complete list of today’s Zacks #1 Rank stocks here.
MU has an earnings yield of 18.7% compared with the industry’s 4.5% yield. The company surpassed earnings estimates in each of the trailing four quarters, the average surprise being 21%.
Richardson Electronics, currently sporting a Zacks Rank #1, posted a first-quarter fiscal 2027 EPS of 27 cents, topping the Zacks Consensus Estimate by 200%. Revenues of $64.92 million beat the Zacks Consensus Estimate by 10.07%.
RELL has an estimated fiscal 2027 earnings growth rate of 62.5% compared with the industry’s 46.2% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 110%.
Ciena, sporting a Zacks Rank #1 at present, reported third-quarter fiscal 2026 EPS of $2.11, which topped the Zacks Consensus Estimate by 21.26%. Revenues of $1.67 billion surpassed the consensus mark by 1.44%.
CIEN has an estimated fiscal 2026 earnings growth rate of 171.2% compared with the industry’s 35.3% growth. The company’s earnings beat estimates in each of the trailing four quarters and matched on one occasion, the average surprise being 17.55%.